Skip to content

Comparison of Glycemic Control Achieved With 2 Different Needles

Comparison of Glycemic Control Achieved With a 31 Gauge x 6 mm NovoFine® Needle vs. a BD 29 Gauge x 12.7 mm Ultra-Fine® Needle in Subjects With Diabetes Mellitus and a BMI Exceeding 30 kg/m2: An Open Label, Randomized, Two-Period Crossover Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00572052
Enrollment
62
Registered
2007-12-12
Start date
2002-12-31
Completion date
2003-10-31
Last updated
2017-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delivery Systems, Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if a 31 gauge x 6 mm needle will provide comparable blood glucose control to the 29 gauge x 12.7 mm needle in obese subjects with diabetes.

Interventions

DEVICEUltra-Fine needle 12.7 mm

Sponsors

Novo Nordisk A/S
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Diabetes mellitus * Current treatment with insulin or insulin analogues for the last 6 months * BMI greater than or equal to 30.0 kg/m2 * Currently injecting in the thigh or abdomen * HbA1c below 10%

Exclusion criteria

* Severe, uncontrolled hypertension * Self-mixing insulin * Unwillingness to monitor blood glucose * Pregnancy, breast-feeding, intention to become pregnant, or inadequate contraceptive measures

Design outcomes

Primary

MeasureTime frame
HbA1cafter 12 weeks of treatment

Secondary

MeasureTime frame
Subject preference and handling
Frequency of hypoglycaemic episodes
Quality of Life

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026